Naval Daver, MD

home / authors / naval-daver-md

Articles

Dr Daver on the Evolution of Survivorship and Treatment Outcomes in AML

Naval Daver, MD

August 29th 2024

Naval G. Daver, MD, discusses the evolution of survivorship in patients with acute myeloid leukemia.

Dr. Daver on Unmet Needs in the Treatment of BPDCN

Naval Daver, MD

February 2nd 2023

Naval Daver, MD, discusses the unmet needs for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Gina Mauro, of OncLive, and Naval Daver, MD, of The University of Texas MD Anderson Cancer Center

Updates in AML and MPNs From ASH 2021: From Drs Srdan Verstovsek and Naval Daver

Gina Mauro;Srdan Verstovsek, MD, PhD;Naval Daver, MD

December 13th 2021

OncLive® speaks with Dr. Srdan Verstovsek on the pivotal data in myeloproliferative neoplasms, and Dr. Naval Daver on some intriguing findings in acute myeloid leukemia.

Dr. Daver on the Mechanism of Action of Magrolimab in AML/MDS

Naval Daver, MD

June 17th 2020

Naval G. Daver, MD, discusses the mechanism of action of the investigational CD47-directed antibody magrolimab in acute myeloid leukemia and myelodysplastic syndrome.

Dr. Daver Discusses Single-Agent Immunotherapy in AML

Naval Daver, MD

December 19th 2017

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses single-agent immunotherapy in acute myeloid leukemia.

Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL

Naval Daver, MD

November 16th 2017

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.

Dr. Daver on Immune Checkpoint Pathways in AML

Naval Daver, MD

December 28th 2016

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.